Loading stock data…
ABBV
$206.11-2.05 (-0.98%)
Pre-Market$206.28+0.17 (+0.08%)· Last close May 5
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AbbVie Inc. in the Healthcare sector is trading at $206.11. The stock is currently 16% below its 52-week high of $244.81, remaining 4.1% below its 200-day moving average. Technical signals show neutral RSI of 47 and bullish MACD crossover, explaining why ABBV maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$206.11
Potential Downside
106%
Whystock Fair Value$-12.27
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus30 analysts
Buy
Mean target$252.47+22.5%
Range$184.00 – $328.00
Fundamentals
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$354.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
84.24
Beta
Defensive asset. Lower volatility than the S&P 500.
0.36
Div Yield
Strong income play. Yield provides a meaningful total return floor.
337.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-115.08%
Volume
Today's trading volume
3.20M
Recent News
DDW 2026: key readouts from the conference
Clinical Trials Arena rounds up the key readouts from the 2026 Digestive Disease Week conference held in Chicago.
Want Reliable Dividend Income in May? These 2 Stocks Deliver
These stocks check off multiple boxes for income investors.
3 Stocks Estimated To Be Trading Up To 49.9% Below Intrinsic Value
Over the last 7 days, the United States market has remained flat, yet it has seen a significant rise of 28% over the past year, with earnings projected to grow by 16% annually in the coming years. In such an environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervaluation.
Want to Collect a High Dividend Every Month? Invest in These 3 Stocks
By holding these top income stocks in your portfolio, you can have a position in some great companies while also generating cash flow each month.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.